parkinson's disease retatrutide clinical trial drug therapies in the pipeline: 2023 update Triumph-1 Trial Results for Retatrutide

While the idea of self-injection intimidates some people initially, the technique is straightforward and becomes routine quickly

However, this outcome fell short of the anticipated 25% weight reduction, potentially limiting its competitive edge against Eli Lillys ZEPBOUND, which reported up to 20.9% weight loss in the SURMOUNT-1 trial. In the subsequent REDEFINE 2 trial, which focused on adults with obesity or overweight and type 2 diabetes, CagriSema achieved a 15.7% mean weight loss after 68 weeks, compared to 3.1% with placebo

Tsai, C

However, true biotin deficiency can cause hair loss, and reduced dietary intake during GLP-1 therapy could push levels lower

Another common response during this initial period is loss of appetite, which may feel unusual if youre not used to changes in hunger cues